You feel well. Your clock says young.
Sequence once. Measure over time. Reinterpret for life.
Your DNA, tested once. Your blood and biological age, checked over time — at home, with no appointments. Read together in one record, so you see what one test alone would miss.


“The example member’s genome and methylation results sit beside her recent blood results and wearable history — one record to bring to her doctor.”
Illustrative example. Medical results are recorded for context, not independently interpreted as medical care. Your doctor makes medical decisions.
Tested once. Checked over time. Read together.
- Step 01
Tested once
Your whole genome is read once, at home. It never changes; what science can read from it does.
- Step 02
Checked over time
Blood and biological age are re-measured over time, and your watch or ring adds how you live and recover.
- Step 03
Read together
One record compares every result with your own history and your genetics, not with an average person.
Read together, the record finds what one test misses.
Optimal below 300
The blood tells a different story. Lp(a) is mostly inherited and barely moves with diet.
One thing to discuss
Lp(a) 3.4× the limitYoung clock, inherited lipid risk. Knowing it early gives you and your doctor time to plan.
Illustrative example based on sample laboratory reports. Not a diagnosis.
Only the changes worth your attention.
Your biological age is younger than your calendar age, but your Lp(a) is well above the limit and largely inherited. One thing to discuss with your doctor.
4 AEVUM speaks only when something meaningful changes.
Ask 4 AEVUM
Illustrative conversation
“My biological age is young — why is Lp(a) flagged?”
A young clock and an inherited risk can sit side by side. Lp(a) is largely set by your genes, so it is worth discussing with your doctor even when you feel well. This is not a diagnosis.
Four parts of one personal record
The genome includes the longevity signature. Methylation gives a repeatable baseline. A blood biomarker panel, other medical records and wearable data keep the picture in context.
Your whole genome
Sequenced once. The curated longevity signature is read from this genome, not ordered as a separate test. New evidence can change how the same sequence is understood.
Your biological age
A repeatable measurement from blood. A single result gives you a baseline; later measurements can show a direction, with uncertainty stated plainly.
Your medical record
A comprehensive blood biomarker panel and the results and history you share stay organised alongside the measurements. They provide context; Aevum does not independently interpret them as medical care. Panel details will be confirmed before purchase.
Your everyday data
Sleep, activity and habits add day-to-day context and a timeline to the record. Connect what you use and see how the picture develops over time.
Why this matters to you
Illustrative situations showing why a joined-up record can make your next conversation more informed.
Bloodwork in range, an ageing signal worth following
Standard annual results all within range. Nothing flagged, nothing followed up.
DNA-methylation age is ahead of chronological age. The genome supplies inherited context; the blood results remain visible in the medical record for a clinician to review.
A clearer question to take to a clinician: how should this baseline be followed? The record does not diagnose or reinterpret the blood panel.
A family history without a mechanism
Cardiovascular events on both sides of the family. Cholesterol treated as the whole story.
The genome, including the longevity signature, offers evidence-graded inherited context. Methylation provides a separate baseline; existing blood results remain in the record.
A more specific conversation about family history, without treating a genetic association as a diagnosis or a prediction.
Two years later, the same data reads differently
A first report with several variants placed in a lower-confidence tier.
New published evidence changes how two genomic variants are graded; a repeat methylation measurement adds a second point on the timeline. New blood results are filed alongside them.
Nothing was re-sequenced. The genomic reading can mature while new measurements and records make changes visible over time.
“Normal for your age” at 54
After menopause, her blood results and day-to-day data have changed. She wants a clearer record to take to her clinician.
Repeat DNA-methylation measurements show a direction of change; her genomic signature offers inherited context. Blood results and wearable trends are kept together rather than presented as separate verdicts.
She can bring a clearer timeline to her clinician and decide together whether any additional measurements or medical follow-up make sense.
All scenarios are illustrative. They are not promised outcomes or medical advice.
See how a finding is actually presented
See how genomic and methylation findings are explained, while medical results and wearable trends remain available as context.
Inherited tendency toward higher circulating LDL cholesterol
A polygenic pattern across well-replicated lipid loci places this illustrative profile in the upper part of the distribution for genetically influenced LDL-C.
Percentile within the reference population used for this illustration
Lipid levels are likely to sit higher than average for a given lifestyle, so lipid values are worth watching earlier and more regularly than usual.
It is not a diagnosis of hyperlipidaemia or cardiovascular disease, and it does not fix a future outcome. Predisposition describes tendency, not destiny.
An ApoB result can be kept alongside this inherited tendency in the medical record for discussion with a clinician; Aevum does not interpret the blood value as medical care.
Lipid panel including ApoB and Lp(a), reviewed against current guideline thresholds with a clinician.
Hundreds of values become a short, ordered picture
The work is making inherited and methylation findings understandable without turning a medical record into an independent diagnosis.
Where signals agree
A genomic tendency can be viewed beside dated blood results, ready for a clinician to assess in context.
Where signals disagree
A genome and a methylation measurement can point in different directions. Neither cancels out the other.
Where nothing is happening
Many genetic associations are small or uncertain. The report can say so, rather than turn everything into an alert.
Today you can buy fragments of the picture
Many services focus on a single kind of data. Aevum is designed to keep the genomic, methylation and personal record together.
Blood platforms
Current biomarkers and a blood-derived “biological age”.
Usually no genome or methylation measurement in the same record.
Epigenetic age tests
A single methylation clock reading.
Often no genome or broader personal record alongside it.
Consumer genome kits
Sequencing, sometimes at depth.
Often no separate methylation baseline or connected personal record.
Premium clinics
Physician-led assessment, often with testing and imaging.
A different, usually visit-based clinical service rather than a portable personal record.
The point is not to replace a physician-led programme. It is to make your genomic and methylation findings understandable, with your other information kept in one place.
Where each approach reaches — and stops
A factual comparison of what categories of product typically include.
| Capability | Blood platforms Biomarker panels | Epigenetic age tests Single clock | Consumer WGS kits Sequencing-led | Premium longevity clinics In-person programmes | Aevum Integrated report |
|---|---|---|---|---|---|
| 30× whole genome | |||||
| Longevity signature from genome | |||||
| DNA-methylation age | |||||
| Medical results on file | |||||
| Wearable data connected | |||||
| One evolving record |
Included · Partial · Not included. Describes typical scope of each category of product, not the specifications of any individual company, which vary and change.
183 longevity variants, honestly graded
Not a disease-risk report renamed “longevity”, and not the two or three famous genes every kit ships.
Each variant in the signature is selected for association with exceptional longevity, survival or parental lifespan — then assessed on evidence strength, effect size, replication across cohorts and relevance to your population.
Effects in longevity genetics are small. We report them that way. Variants sit in confidence tiers; uncertain markers are not forced into a score, and correlated variants are not counted twice.
The purpose is not to predict a date. It is an evidence-graded view of inherited longevity biology.
How the signature is builtSequenced once. Re-read for years.
Your genome does not change. Almost everything used to interpret it does.
New replicated studies can change the explanation of your genome without sequencing again. Optional repeat methylation measurements, new blood results and wearable data add dated context to your record over time.
- 01Baseline
30× genome with longevity signature, methylation age, medical records and wearable data in one view.
- 02Later
Optional repeat methylation and new results add dated points of comparison.
- 03As evidence evolves
Genomic findings can be re-read against newer research without sequencing again.
- 04Ongoing
Your record keeps the original measurements and later additions together.
AI can organise and explain evidence. It does not create it.
Every interpretation is linked to published evidence, graded for confidence, version-controlled and explicit about its limits.
Each statement traces to the studies behind it.
Strength of evidence is shown, never implied.
You can see which interpretation produced a finding.
What the data cannot tell you is written down.
What people ask before they register
Short answers about the planned programme and its limits.
What exactly do I receive?
One integrated report brings together your 30× whole genome (including the 183-variant longevity signature), DNA-methylation age, a comprehensive blood biomarker panel alongside medical history, and wearable data. Medical records are organised for context, not independently interpreted as medical care. Panel details will be confirmed before purchase.
What does it cost?
Approximately €4,000 for the full programme. Optional clinician sessions, extended biomarkers and repeat measurements are priced separately. A compatible existing whole genome may reduce the price. Nothing recurs automatically.
Do I need to visit a clinic?
No appointments or clinic visits. The programme is home-first: one home kit, plus the devices and results you already have. Kit details will be confirmed before purchase. You can share your results with your own doctor.
I already have my genome sequenced. Does that help?
Yes. If your existing file is a compatible whole-genome sequence at sufficient depth, we verify its quality and reduce the programme price accordingly — you do not pay to sequence twice.
Is this medical advice?
No. The report is an integrated interpretation, not a diagnosis. It is designed to be shared with your doctor, who stays in charge of medical decisions.
What happens after I join the waiting list?
Access is planned in small groups. The current form is a preview and does not send your details yet. It does not reserve a kit or make a purchase.
Be among the first to see your complete picture
Access is planned in small groups. The interest form is a preview for now; it does not yet send your details or reserve a place.